(RXST) Rxsight - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 252m USD | Total Return: -62.6% in 12m

Intraocular Lenses, Light Delivery Devices, Cataract Surgery System
Total Rating 12
Safety 27
Buy Signal -1.02
Medical Devices
Industry Rotation: +5.3
Market Cap: 252M
Avg Turnover: 3.72M
Risk 3d forecast
Volatility61.7%
VaR 5th Pctl10.0%
VaR vs Median-1.75%
Reward TTM
Sharpe Ratio-0.97
Rel. Str. IBD2
Rel. Str. Peer Group6.5
Character TTM
Beta0.797
Beta Downside1.531
Hurst Exponent0.490
Drawdowns 3y
Max DD91.41%
CAGR/Max DD-0.42
CAGR/Mean DD-0.86
EPS (Earnings per Share) EPS (Earnings per Share) of RXST over the last years for every Quarter: "2021-03": -0.36, "2021-06": -0.51, "2021-09": -0.68, "2021-12": -0.58, "2022-03": -0.64, "2022-06": -0.61, "2022-09": -0.61, "2022-12": -0.56, "2023-03": -0.31, "2023-06": -0.28, "2023-09": -0.19, "2023-12": -0.26, "2024-03": -0.12, "2024-06": -0.16, "2024-09": -0.16, "2024-12": 0.03, "2025-03": -0.03, "2025-06": -0.08, "2025-09": -0.24, "2025-12": -0.03, "2026-03": -0.19,
Last SUE: -0.31
Qual. Beats: 0
Revenue Revenue of RXST over the last years for every Quarter: 2021-03: 3.484, 2021-06: 4.897, 2021-09: 5.786, 2021-12: 8.426, 2022-03: 8.942, 2022-06: 11.36, 2022-09: 12.615, 2022-12: 16.088, 2023-03: 17.489, 2023-06: 20.81, 2023-09: 30.667, 2023-12: 28.58, 2024-03: 29.512, 2024-06: 34.887, 2024-09: 45.408, 2024-12: 40.214, 2025-03: 37.895, 2025-06: 33.637, 2025-09: 30.34, 2025-12: 32.607, 2026-03: 30.893,
Rev. CAGR: 25.88%
Rev. Trend: 78.2%
Last SUE: 0.33
Qual. Beats: 0

Warnings

High Debt while negative Cash Flow

Interest Coverage Ratio -3459.1 is critical

Altman Z'' -15.00 < 1.0 - financial distress zone

Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: RXST Rxsight

RxSight, Inc. (RXST) is a commercial-stage medical technology firm specializing in ophthalmic surgery. The company designs and manufactures the Light Adjustable Lens (LAL) system, which allows ophthalmologists to perform non-invasive, post-operative adjustments to a patients vision following cataract surgery.

The core technology utilizes photosensitive materials that react to ultraviolet light delivered via an office-based device. This business model shifts the paradigm of cataract care from pre-operative estimation to post-operative customization, addressing the inherent variability in human eye healing. The ophthalmic device sector is characterized by high barriers to entry due to stringent clinical validation and regulatory requirements for implantable materials.

Investors may find additional context on these market dynamics by reviewing the latest data on ValueRay. RxSight is headquartered in Aliso Viejo, California, and operates within the broader Health Care Supplies industry, focusing on premium intraocular lens solutions.

Headlines to Watch Out For
  • Increased adoption of Light Adjustable Lens technology drives premium intraocular lens revenue
  • Expansion of installed base for Light Delivery Devices enables recurring procedure growth
  • High gross margins on consumables improve path toward sustained GAAP profitability
  • Competitive pressure from established incumbents impacts market share in premium cataract segment
  • Regulatory approval for new lens materials expands addressable patient population and applications
Piotroski VR-10 (Strict) 1.0
Net Income: -46.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.07 > 0.02 and ΔFCF/TA -0.55 > 1.0
NWC/Revenue: 197.6% < 20% (prev 167.7%; Δ 29.85% < -1%)
CFO/TA -0.06 > 3% & CFO -17.6m > Net Income -46.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 10.20 > 1.5 & < 3
Outstanding Shares: last quarter (41.3m) vs 12m ago 1.97% < -2%
Gross Margin: 77.02% > 18% (prev 0.67%; Δ 7.63k% > 0.5%)
Asset Turnover: 41.32% > 50% (prev 50.60%; Δ -9.28% > 0%)
Interest Coverage Ratio: -3.46k > 6 (EBITDA TTM -52.0m / Interest Expense TTM 16.0k)
Altman Z'' -15.00
A: 0.83 (Total Current Assets 279.2m - Total Current Liabilities 27.4m) / Total Assets 304.0m
B: -2.23 (Retained Earnings -676.9m / Total Assets 304.0m)
C: -0.18 (EBIT TTM -55.3m / Avg Total Assets 308.5m)
D: -18.45 (Book Value of Equity -676.9m / Total Liabilities 36.7m)
Altman-Z'' = -22.40 = D
Beneish M -3.11
DSRI: 0.90 (Receivables 22.4m/31.0m, Revenue 127.5m/158.4m)
GMI: 0.87 (GM 77.02% / 67.29%)
AQI: 1.59 (AQ_t 0.01 / AQ_t-1 0.00)
SGI: 0.80 (Revenue 127.5m / 158.4m)
TATA: -0.10 (NI -46.6m - CFO -17.6m) / TA 304.0m)
Beneish M = -3.11 (Cap -4..+1) = AA
What is the price of RXST shares?

As of May 27, 2026, the stock is trading at USD 5.99 with a total of 621,803 shares traded.
Over the past week, the price has changed by -0.17%, over one month by -17.83%, over three months by -24.37% and over the past year by -62.59%.

Is RXST a buy, sell or hold?

Rxsight has received a consensus analysts rating of 3.73. Therefore, it is recommended to hold RXST.

  • StrongBuy: 4
  • Buy: 2
  • Hold: 3
  • Sell: 2
  • StrongSell: 0

What are the forecasts/targets for the RXST price?
Analysts Target Price 8.8 46.7%
Rxsight (RXST) - Fundamental Data Overview as of 27 May 2026
Market Cap USD = 251.9m (251.9m USD * 1.0 USD.USD)
P/E Forward = 116.2791
P/S = 1.976
P/B = 0.9416
Revenue TTM = 127.5m USD
EBIT TTM = -55.3m USD
EBITDA TTM = -52.0m USD
Long Term Debt = 9.32m USD (estimated: total debt 10.8m - short term 1.50m)
Short Term Debt = 1.50m USD (from shortTermDebt, last quarter)
Debt = 10.8m USD (from shortLongTermDebtTotal, last quarter) (leases 10.8m already included)
Net Debt = -207.1m USD (calculated: Debt 10.8m - CCE 217.9m)
Enterprise Value = 44.8m USD (251.9m + Debt 10.8m - CCE 217.9m)
Interest Coverage Ratio = -3.46k (Ebit TTM -55.3m / Interest Expense TTM 16.0k)
EV/FCF = -2.08x (Enterprise Value 44.8m / FCF TTM -21.6m)
FCF Yield = -48.13% (FCF TTM -21.6m / Enterprise Value 44.8m)
FCF Margin = -16.93% (FCF TTM -21.6m / Revenue TTM 127.5m)
Net Margin = -36.58% (Net Income TTM -46.6m / Revenue TTM 127.5m)
Gross Margin = 77.02% ((Revenue TTM 127.5m - Cost of Revenue TTM 29.3m) / Revenue TTM)
Gross Margin QoQ = 76.06% (prev 77.48%)
Tobins Q-Ratio = 0.15 (Enterprise Value 44.8m / Total Assets 304.0m)
Interest Expense / Debt = 0.15% (Interest Expense 16.0k / Debt 10.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -43.7m (EBIT -55.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.20 (Total Current Assets 279.2m / Total Current Liabilities 27.4m)
Debt / Equity = 0.04 (Debt 10.8m / totalStockholderEquity, last quarter 267.3m)
 Debt / EBITDA = 3.98 (negative EBITDA) (Net Debt -207.1m / EBITDA -52.0m)
 Debt / FCF = 9.59 (negative FCF - burning cash) (Net Debt -207.1m / FCF TTM -21.6m)
 Total Stockholder Equity = 274.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -15.12% (Net Income -46.6m / Total Assets 304.0m)
RoE = -4.90% (Net Income TTM -46.6m / Total Stockholder Equity 951.2m)
RoCE = -5.76% (EBIT -55.3m / Capital Employed (Equity 951.2m + L.T.Debt 9.32m))
 RoIC = -15.91% (negative operating profit) (NOPAT -43.7m / Invested Capital 274.8m)
 WACC = 8.43% (E(251.9m)/V(262.7m) * Re(8.79%) + D(10.8m)/V(262.7m) * Rd(0.15%) * (1-Tc(0.21)))
Discount Rate = 8.79% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 6.35%
 [DCF] Fair Price = unknown (Cash Flow -21.6m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.31 | # QB: 0
Revenue Correlation: 78.17 | Revenue CAGR: 25.88% | SUE: 0.33 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.20 | Chg30d=-17.65% | Revisions=+0% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.17 | Chg30d=+4.29% | Revisions=+20% | Analysts=4
EPS current Year (2026-12-31): EPS=-0.70 | Chg30d=-8.53% | Revisions=-20% | GrowthEPS=-288.9% | GrowthRev=-3.9%
EPS next Year (2027-12-31): EPS=-0.56 | Chg30d=-16.06% | Revisions=-20% | GrowthEPS=+20.0% | GrowthRev=+10.1%
[Analyst] Revisions Ratio: +20%